Anti-GD2 immunotherapy for neuroblastoma

CAR T-cell therapy of solid tumors

(2017) Carmen S M Yong et al.   IMMUNOLOGY AND CELL BIOLOGY

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

(2017) Rajen Mody et al.   LANCET ONCOLOGY

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma

(2016) Christopher J. Forlenza et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

(2016) Nikolai Siebert et al.   mAbs

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

(2016) Konstantin Dobrenkov et al.   PEDIATRIC BLOOD & CANCER

Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering

(2016) H. Xu et al.   Cancer Immunology Research

Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma

(2016) Jaume Mora   Expert Review of Clinical Pharmacology

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

(2016) Ming Cheng et al.   OncoImmunology

Role of IL-2 in cancer immunotherapy

(2016) Tao Jiang et al.   OncoImmunology

Activated T cells armed with bispecific antibodies kill tumor targets

(2015) Divaya Bhutani et al.   CURRENT OPINION IN HEMATOLOGY

Disialoganglioside GD2 as a therapeutic target for human diseases

(2015) Maya Suzuki et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy

(2015) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

(2015) Brian H. Kushner et al.   Oncotarget

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

(2015) Brian H Kushner et al.   OncoImmunology

In Situ Modulation of Dendritic Cells by Injectable Thermosensitive Hydrogels for Cancer Vaccines in Mice

(2014) Yarong Liu et al.   BIOMACROMOLECULES

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Gangliosides Drive the Tumor Infiltration and Function of Myeloid-Derived Suppressor Cells

(2014) A. Wondimu et al.   CANCER RESEARCH

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

Key role for myeloid cells: Phase II results of anti-GD2antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

(2014) Nai-Kong V. Cheung et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex

(2014) S. M. Cheal et al.   MOLECULAR CANCER THERAPEUTICS

Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma

(2014) Doralina L. Anghelescu et al.   PEDIATRIC BLOOD & CANCER

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

(2014) Mickaël Terme et al.   PLoS One

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2

(2014) Mahiuddin Ahmed et al.   Frontiers in Immunology

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1

(2013) Yibing Xu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

(2013) Mahiuddin Ahmed et al.   FEBS LETTERS

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

(2013) Marie Vincent et al.   INTERNATIONAL JOURNAL OF CANCER

Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma

(2013) Daniela Di Paolo et al.   JOURNAL OF CONTROLLED RELEASE

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

(2013) Susan G Kreissman et al.   LANCET ONCOLOGY

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

(2013) Ruth Ladenstein et al.   mAbs

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

(2013) Mahiuddin Ahmed et al.   PLoS One

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan

(2013) Shakeel Modak et al.   OncoImmunology

How Do Gangliosides Regulate RTKs Signaling?

(2013) Sylvain Julien et al.   Cells

Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3

(2012) Hidenobu Shibuya et al.   CANCER SCIENCE

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

(2012) Nidale Tarek et al.   JOURNAL OF CLINICAL INVESTIGATION

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis

(2012) Venkata Lokesh Battula et al.   JOURNAL OF CLINICAL INVESTIGATION

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Essential Roles of Gangliosides in the Formation and Maintenance of Membrane Microdomains in Brain Tissues

(2012) Yuhsuke Ohmi et al.   NEUROCHEMICAL RESEARCH

Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles

(2012) Amanda Tivnan et al.   PLoS One

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

(2012) Nai-Kong V. Cheung et al.   OncoImmunology

Expression of GD2 and GD3 Gangliosides in Human Embryonic Neural Stem Cells

(2011) Makoto Yanagisawa et al.   ASN Neuro

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

(2011) Thorsten Simon et al.   BMC CANCER

Successful Multifold Dose Escalation of Anti-GD2Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study

(2011) Brian H. Kushner et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains

(2011) Jeroen J Lammerts van Bueren et al.   NATURE BIOTECHNOLOGY

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc  Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

(2010) D. C. Delgado et al.   CANCER RESEARCH

Neuroblastoma: Therapeutic strategies for a clinical enigma

(2010) Shakeel Modak et al.   CANCER TREATMENT REVIEWS

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells

(2009) Aleksandra Kowalczyk et al.   CANCER LETTERS

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

(2009) Kim Kramer et al.   JOURNAL OF NEURO-ONCOLOGY

In vitrophotothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody

(2009) Chung-Hao Wang et al.   NANOTECHNOLOGY

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

(2008) Andrew DJ Pearson et al.   LANCET ONCOLOGY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE